The CRISPR-Cas13a Gemini System for noncontiguous target RNA activation

Area of Science:

• Molecular Biology
• Biotechnology
• Genetics

Background:

• CRISPR-Cas13a systems traditionally rely on contiguous RNA targets, limiting applications to single-target detection and editing.
• Simultaneous multi-target detection and multi-site gene editing are critical unmet needs in diagnostics and therapeutics.

Purpose of the Study:

• To develop a novel CRISPR-Cas13a system for simultaneous detection of multiple RNA targets and parallel gene editing.
• To establish a noncontiguous target RNA activation paradigm for Cas13a.

Main Methods:

• Developed the CRISPR-Cas13a Gemini System using two Cas13a:crRNA binary complexes.
• Demonstrated RNA detection for breast cancer (miR-155, miR-375) and Epstein-Barr virus (EBER-1, EBER-2) using fluorescence and colorimetric platforms.
• Showcased simultaneous knockdown of EGFP and mCherry transcripts in mammalian cells.

Main Results:

• The CRISPR-Cas13a Gemini System enables rapid, simultaneous, highly specific, and sensitive detection of two distinct RNA molecules.
• Successfully applied the system for diagnosing breast cancer and Epstein-Barr virus.
• Achieved parallel dual transgene knockdown in mammalian cells.

Conclusions:

• The CRISPR-Cas13a Gemini System overcomes limitations of previous Cas13a systems by enabling noncontiguous RNA targeting.
• This technology holds significant potential for highly effective simultaneous biomarker detection and multi-site gene editing applications.